- Vertex-CRISPR drug posts phase 3 wins, secures PDUFA date FierceBiotech
- CRSP Stock Pops As FDA Sets December Data To Potentially OK Gene-Editing Drug | Investor’s Business Daily Investor’s Business Daily
- FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia Yahoo Finance
- Gene Editing Race Between Editas and Vertex, CRISPR Heats Up BioSpace
- Editas posts early sickle cell data as it races to catch Vertex FierceBiotech
- View Full Coverage on Google News
Read original article here